KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

AbbVie (ABBV) R&D In Process (2016 - 2025)

AbbVie (ABBV) has disclosed R&D In Process for 14 consecutive years, with $3.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, R&D In Process rose 137.17% to $3.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.0 billion, a 142.32% increase, with the full-year FY2025 number at $5.0 billion, up 81.94% from a year prior.
  • R&D In Process was $3.7 billion for Q4 2025 at AbbVie, up from $700.0 million in the prior quarter.
  • In the past five years, R&D In Process ranged from a high of $3.7 billion in Q4 2025 to a low of $40.0 million in Q3 2022.
  • A 5-year average of $483.5 million and a median of $249.0 million in 2024 define the central range for R&D In Process.
  • Peak YoY movement for R&D In Process: soared 788.89% in 2021, then plummeted 90.0% in 2022.
  • AbbVie's R&D In Process stood at $407.0 million in 2021, then crashed by 40.29% to $243.0 million in 2022, then increased by 16.05% to $282.0 million in 2023, then soared by 458.16% to $1.6 billion in 2024, then surged by 137.17% to $3.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's R&D In Process are $3.7 billion (Q4 2025), $700.0 million (Q3 2025), and $335.0 million (Q2 2025).